215 patents
Page 10 of 11
Utility
Biomarker of PNPLA3 Expression
23 Sep 20
The present disclosure relates to a novel biomarker for measuring PNPLA3 gene expression and methods of using the novel biomarker for treating, preventing, or ameliorating a disease associated with PNPLA3.
Mathias LILJEBLAD
Filed: 17 Dec 19
Utility
Combination of a BTK Inhibitor and an Inhibitor or CDK9 to Treat Cancer
16 Sep 20
The present invention relates to combination of a BTK inhibitor and an inhibitor of CDK9 for use in the treatment of cancer in a subject.
Scott BOIKO, Justin CIDADO, Lisa DREW, Teresa PROIA, Maryann SAN MARTIN
Filed: 23 Sep 18
Utility
GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof
26 Aug 20
The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.
Brett P. MONIA, Thazha P. PRAKASH, Garth A. KINBERGER, Richard LEE, Punit P. SETH, Michael OESTERGAARD, Mehran NIKAN, Shalini ANDERSSON, Eva Carina AMMALA, Daniel Laurent KNERR, Maria OLWEGARD-HALVARSSON, William John DRURY, III, Eric VALEUR
Filed: 6 Nov 18
Utility
Pharmaceutical Compositions
12 Aug 20
The present application relates to solid pharmaceutical compositions and solid dosage forms containing them which comprise oils as their active pharmaceutical ingredient.
Christian VON CORSWANT, Romain BORDES, Simon Peter Michael HJELM JONASSON
Filed: 5 Jul 17
Utility
Certain (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES As Dipeptidyl Peptidase 1 Inhibitors
5 Aug 20
Hans Roland LONN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
Filed: 21 Apr 20
Utility
Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancer
29 Jul 20
The invention relates to the methods for identifying resistance to cancer therapy, by identification of an E63K NRAS mutation, a G12V NRAS mutation or a gain of copy number of NRAS gene.
Darren Anthony, Edward Cross, Catherine Anne Eberlein
Filed: 1 Apr 15
Utility
Chemical Compounds
29 Jul 20
Bernard Christophe BARLAAM, Daniel Hillebrand O'DONOVAN, Samantha Jayne HUGHES, Thomas Andrew MOSS, Johannes Wilhelmus Maria NISSINK, James Stewart SCOTT, Bin YANG
Filed: 27 Jan 20
Utility
Selective Estrogen Receptor Down-Regulators
29 Jul 20
Johannes Wilhelmus Maria Nissink, James Stewart Scott, Thomas Andrew Moss, Samantha Jayne Hughes, Bernard Christophe Barlaam, Bin Yang
Filed: 28 Jan 20
Utility
Protein Kinase B Inhibitors
29 Jul 20
Paul David Johnson, Andrew Leach, Richard William Arthur Luke, Zbigniew Stanley Matusiak, Jeffrey James Morris
Filed: 6 Apr 20
Utility
Arginase Inhibitors and Methods of Use
15 Jul 20
David W. Christianson, Bruce Edward Tomczuk, Richard Scott Pottorf, Andrew Vargha Colasanti, Gary Lee Olson
Filed: 21 Aug 19
Utility
Phenoxyquinazoline Compounds and Their Use In Treating Cancer
15 Jul 20
Tudor GRECU, Jason Grant KETTLE, Martin John PACKER, Stuart Eric PEARSON, James Michael SMITH
Filed: 25 Apr 18
Utility
Mpo Inhibitors for Use In Medicine
1 Jul 20
The present disclosure relates to new therapeutic uses of MPO inhibitors and methods of treatment involving the same.
Andrew WHITTAKER, Hitesh Jayantilal SANGANEE
Filed: 11 Jul 18
Utility
Novel Compounds
10 Jun 20
Frank NARJES, Roine Ingemar OLSSON, Stefan VON BERG, Sarah LEVER
Filed: 24 Nov 19
Utility
Pharmaceutical Composition
10 Jun 20
The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
Filed: 8 Oct 19
Utility
Certain (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES for Treating Bronchiectasis
10 Jun 20
Hans Roland LONN, Stephen CONNOLLY, Steven SWALLOW, Reinilde HEYRMAN, Eugene SULLIVAN, Carlos FERNANDEZ
Filed: 14 Jul 19
Utility
ANTI-IFNAR1 Antibodies with Reduced FC Ligand Affinity
3 Jun 20
The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
ANTHONY COYLE, PETER KIENER, HERREN WU, RICARDO CIBOTTI
Filed: 7 Apr 19
Utility
Pyrazole Derivatives Useful As 5-LIPOXYGENASE Activating Protein (Flap) Inhibitors
20 May 20
Johan Olof BRODDEFALK, Hans Fredrik EMTENÂS, Kenneth Lars GRANBERG, Malin Anita LEMURELL, Daniel Tor PETTERSEN, Alleyn Thomas PLOWRIGHT, Lars Johan Andreas ULANDER
Filed: 29 Oct 19
Utility
Methods For Treating Chronic Obstructive Pulmonary Disease Using Benralizumab
22 Apr 20
Provided herein is are methods of treating Chronic Obstructive Pulmonary Disease (COPD) in a patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.
Rene van der Merwe, Christine Ward, Ubaldo Martin, Lorin Roskos, Bing Wang
Filed: 23 May 19
Utility
Novel Compounds
15 Apr 20
Sarah LEVER, Frank NARJES, Roine Ingemar OLSSON, Stefan VON BERG
Filed: 12 Jun 18
Utility
Heteroaryl Compounds That Inhibit G12C Mutant Ras Proteins
8 Apr 20
Jason Grant KETTLE, Sharanjeet Kaur BAGAL, Scott BOYD, Andrew John EATHERTON, Shaun Michael FILLERY, Graeme Richard ROBB, Piotr Antoni RAUBO
Filed: 7 May 18